Preferred Label : baricitinib;
Obsolete resource : false;
MeSH synonym : 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-;
MeSH hyponym : 3-azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-,
phosphate (1:1); baricitinib phosphate salt; INCB-28050; INCB-028050; LY-3009104;
MeSH Related Number : XIB47S8NNB;
Is substance : O;
UNII : ISP4442I3Y;
InChIKey : XUZMWHLSFXCVMG-UHFFFAOYSA-N;
Origin ID : C000596027;
UMLS CUI : C4044947;
ATC code(s)
MeSH term(s) associated for indexing
Record concept(s)
See also (suggested by CISMeF)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-marr/baricitinib
2023
false
false
false
France
French
risk management
guidelines for drug use
patient education handout
baricitinib
baricitinib
continuity of patient care
Janus Kinase Inhibitors
Drug-Related side effects and adverse reactions
Janus Kinase Inhibitors
baricitinib
---
https://www.has-sante.fr/jcms/p_3472152/fr/olumiant-baricitinib-pelade
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
adult
immunosuppressive agents
baricitinib
evaluation of the transparency committee
baricitinib
alopecia areata
---
https://www.usherbrooke.ca/baladocritique/archives/episode-50-etude-recovery
2022
Canada
sound
baricitinib
baricitinib
COVID-19
episode of
persons
hospital admission, nos
data collection
hospitalization
efficiency
---
https://www.has-sante.fr/jcms/p_3237060/fr/olumiant-dermatite-atopique-moderee-a-severe-de-l-adulte
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
baricitinib
adult
dermatitis, atopic
administration, oral
Janus Kinase Inhibitors
baricitinib
evaluation of the transparency committee
azetidines
sulfonamides
---
2021
false
false
false
France
French
administration, oral
baricitinib
risk management
pregnancy
baricitinib
guidelines for drug use
breast feeding
patients guideline
dermatitis, atopic
arthritis, rheumatoid
baricitinib
Janus Kinase Inhibitors
Janus Kinase Inhibitors
drug monitoring
deep vein thrombosis
pulmonary embolism
cholesterol, HDL
cholesterol, LDL
Infections
vaccines, attenuated
venous thrombosis
azetidines
sulfonamides
purines
pyrazoles
azetidines
sulfonamides
purines
pyrazoles
---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_18_Spondyloarthrites_MAJ_220719.pdf
2019
false
false
false
France
adult
tofacitinib
tofacitinib
administration, oral
baricitinib
baricitinib
spondylitis, ankylosing
arthritis, psoriatic
guideline
Janus Kinase Inhibitors
spondylarthropathies
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides
---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_08_Aff%20Hemato_MAJ_200819.pdf
2019
false
false
false
France
Janus Kinase Inhibitors
baricitinib
tofacitinib
Janus Kinase Inhibitors
risk factors
blood cell count
continuity of patient care
neutropenia
lymphopenia
anemia
algorithms
guideline
hematologic diseases
lymphoma
arthritis, rheumatoid
azetidines
sulfonamides
pyrimidines
pyrroles
piperidines
---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_07_Cancer_MAJ_220719.pdf
2019
false
false
false
France
neoplasms
risk
Janus Kinase Inhibitors
Janus Kinase Inhibitors
tofacitinib
baricitinib
guideline
arthritis, rheumatoid
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides
---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_06_%20Cardio_MAJ_220719.pdf
2019
false
false
false
France
Janus Kinase Inhibitors
cardiovascular agents
anticoagulants
tofacitinib
baricitinib
cholesterol
Janus Kinase Inhibitors
risk
risk factors
drug interactions
guideline
arthritis, rheumatoid
cardiovascular diseases
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides
---
http://www.cri-net.com/ckfinder/userfiles/files/fiches-pratiques/JAKI-octobre2019/JAK_09_Digestif_Hepatiq_MAJ_220719.pdf
2019
false
false
false
France
Janus Kinase Inhibitors
hepatic insufficiency
hepatitis B
hepatitis C
tofacitinib
baricitinib
Alanine aminotransferase outside reference range (finding)
transaminases
intestinal perforation
arthritis, rheumatoid
guideline
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides
---
http://www.cri-net.com/fiches-pratiques-et-recommandations/prise-en-charge-patients-JAKi
2018
false
false
false
France
continuity of patient care
pregnancy
vaccination
travel
virus diseases
bacterial infections
cardiovascular diseases
neoplasms
lymphoma
digestive system diseases
hematologic diseases
dental care
surgical procedures, operative
tofacitinib
baricitinib
drug therapy, combination
arthritis, rheumatoid
Contraindications, Drug
drug interactions
Evidence-Based medicine
baricitinib
tofacitinib
guidelines for drug use
case management
Janus Kinase Inhibitors
pyrimidines
pyrroles
piperidines
azetidines
sulfonamides
---
https://www.has-sante.fr/portail/jcms/c_2778111/fr/olumiant
https://www.has-sante.fr/portail/jcms/c_2778111/fr/olumiant-baricitinib-anti-jak-1et-2
2017
false
false
false
France
French
baricitinib
treatment outcome
drug therapy, combination
arthritis, rheumatoid
administration, oral
adult
aged
immunosuppressive agents
janus kinase 2
janus kinase 1
evaluation of the transparency committee
methotrexate
guidelines for drug use
Tyrosine Kinase Inhibitors
baricitinib
azetidines
sulfonamides
---
https://www.ema.europa.eu/medicines/human/EPAR/Olumiant
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
baricitinib
drug approval
europe
baricitinib
treatment outcome
drug therapy, combination
arthritis, rheumatoid
administration, oral
adult
aged
immunosuppressive agents
immunosuppressive agents
pregnancy
breast feeding
product surveillance, postmarketing
drug interactions
janus kinase 2
janus kinase 1
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
baricitinib
azetidines
sulfonamides
azetidines
sulfonamides
---